SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from CLINICAL INTELLIGENCE INC (CIK 0001218244) — Jun 29, 2005

CLINICAL INTELLIGENCE INC (CIK 0001218244)
Date: June 29, 2005 · CIK: 0001218244 · Accession: 0001127855-05-000445

AI Filing Summary & Sentiment

File numbers found in text: 333-110128

Date
June 29, 2005
Author
Not clearly detected
Form
CORRESP
Company
CLINICAL INTELLIGENCE INC (CIK 0001218244)

Letter

Securities and Exchange Commission RE: Amendment No. 1 to the Form 8K/A Filed: 16 June, 2005 15:09 File No. 333-110128 Accession No. 0001127855-05-000431

Dear Mr. Gilmore:

With respect to the filing as identified above, we make the following statement:

Clinical Intelligence, Inc., hereby acknowledges

(1) that the company is responsible for the adequacy and accuracy of the disclosure in the filing;

(2) that staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and

(3) that the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Thank you for your courtesy in this matter.

CLINICAL INTELLIGENCE, INC.

/s/ Edward H. Hawkins

Edward H. Hawkins, Secretary

Show Raw Text
CORRESP
1
filename1.htm

		Untitled Page

			CLINICAL INTELLIGENCE, INC.

			1629 York St., Denver, Colorado 80206

			(303) 388-8586

		27 June 2005

			Patrick Gilmore, CPA

			Securities and Exchange Commission

			Washington, DC 20549

		            RE: Amendment No. 1 to the Form 8K/A

			                   Filed: 16 June, 2005 15:09

			                   File No. 333-110128

			                   Accession No. 0001127855-05-000431

		Dear Mr. Gilmore:

		            With respect to the filing as identified above, we make the following statement:

		            Clinical Intelligence, Inc., hereby acknowledges

					(1)
					that the company is responsible for the adequacy and accuracy of the disclosure in the filing;

					(2)
					that staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and

					(3)
					 that the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

			Thank you for your courtesy in this matter.

		                                                                                       CLINICAL INTELLIGENCE, INC.

		                                                                                       /s/ Edward H. Hawkins

			                                                                                       Edward H. Hawkins, Secretary